Antengene Announces Full Year 2023 Financial Results
Antengene to Present Four Preclinical Abstracts at AACR 2024
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs